Showing 941-950 of 1604 results for "".
- CeraVe Funds New Derm Residency Position at George Washington Universityhttps://practicaldermatology.com/news/cerave-funds-new-derm-residency-position-at-george-washington-university/2462012/CeraVe is partnering with George Washington University to support a newly approved Accreditation Council for Graduate Medical Education (ACGME) residency spot in the school's Department of Dermatology Resident Program, slated to begin on July 1, 2024. "
- Encouraging Preclinical Results Seen for Scinai’s NanoAbs in Plaque Psoriasishttps://practicaldermatology.com/news/encouraging-preclinical-results-seen-for-scinais-nanoabs-in-plaque-psoriasis/2462006/Scinai Immunotherapeutics Ltd.’s anti‑interleukin 17 (IL‑17) NanoAbs downregulated key molecular markers that are overexpressed in plaque psoriasis, according to preclinical data relased by Scinai. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-
- Almirall Launches New Campaign, Atopic Museum for World Eczema Dayhttps://practicaldermatology.com/news/almirall-launches-new-campaign-atopic-museum-for-world-eczema-day/2462003/Almirall unveiled its atopic dermatitis awareness campaign "Moving aheAD" for World Atopic Eczema Day. The campaign includes the “Atopic M
- Cetaphil Takes on Aging Skin with New Skincare Linehttps://practicaldermatology.com/news/cetaphil-takes-on-aging-skin-with-new-skincare-line/2461995/Galderma is rolling out Cetaphil Healthy Renew, its first-ever healthy aging skincare line. "Aging skin is a particular point of frustration for my sensitive skin patients due to increased risks of irritation and an already compromised skin barrier,” says Cetaphil partn
- Hoth's Steroid-sparing AD Treatment Shows Promise in Phase 1b Trialhttps://practicaldermatology.com/news/steroid-sparing-ad-treatment-shows-promise-in-phase-1b-trial/2461984/BioLexa led to a 35% improvement in SCORAD ("SCORing Atopic Dermatitis") measurement and a 60% improvement in EASI (Eczema Area and Severity Index) measurement of atopic skin disease during a 14-day treatment period, whereas gentamicin lotion and placebo had no effect, accordi
- Spotlight on Snail Mucushttps://practicaldermatology.com/news/spotlight-on-snail-mucus/2461980/Snail mucus is widely used in cosmetics, moisturizers, anti-aging creams, wound care treatments, and antimicrobials, but what is it, really? This was the question posed by researchers in a new study that examines the molecular composition of snail mucus. When analyzing the mucus of a co
- L'Oréal's SkinCeuticals USA Appoints Angela Hildebrand as General Managerhttps://practicaldermatology.com/news/loreals-skinceuticals-usa-appoints-angela-hildebrand-as-general-manager/2461975/Angela Hildebrand is SkinCeuticals’ new General Manager and Amy Sloan is the Senior Vice President of Business Strategy and Growth. "With their collective knowledge, expertise, and dedication to excellence, Angela and Amy's leadership are poised to tak
- AbbVie Awards 45 Scholarships to U.S. Students Living With Psoriasis, Eczema, and Other Chronic, Immune-Mediated Diseaseshttps://practicaldermatology.com/news/abbvie-awards-45-scholarships-to-us-students-living-with-psoriasis-eczema-and-other-chronic-immune-mediated-diseases/2461970/AbbVie announced the 2023-2024 class of
- Cutera, Inc. Appoints Jeff Jones as COOhttps://practicaldermatology.com/news/cutera-inc-appoints-jeff-jones-as-coo/2461956/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, fi
- Business News: LEO Pharma to Acquire Timber Pharmaceuticalshttps://practicaldermatology.com/news/business-news-leo-pharma-to-acquire-timber-pharmaceuticals/2461943/LEO Pharma is set to acquire Timber Pharmaceuticals, Inc. The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million, and up to an additional $22.0 million in contingent value rights payable upon achievement o